Top Emerging In Vitro Diagnostic Solutions Copmpanies - 2022
Hopkins Medtech Compliance: The Concept-To-commercialization Partner for IVD Manufacturers

Top 10 Emerging In Vitro Diagnostic Solutions Copmpanies - 2022

The global in vitro diagnostic market size was valued at USD 111.67 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 0.2 percent from 2022 to 2030. The growth can be attributed to the increasing adoption of in vitro diagnostics (IVD) owing to the rise in testing due to the pandemic.

The development of automated IVD systems for laboratories and hospitals to provide efficient, accurate, and error-free diagnoses is expected to fuel the market growth. The rising number of IVD products being launched by key players is also fuelling the growth of the market. IVD products with molecular diagnostic capabilities deliver effective and accurate results.

The market is expected to remain buoyant thanks to the success of personalized medicine that is now driving uptake of various IVD tests. IVDs, mainly companion diagnostics, play an integral role in personalized medicine. Increasing governments’ and other stakeholders’ investments in programs that improve healthcare is vital to the IVD industry business growth.

The US government has spearheaded numerous initiatives to provide information and education about personalized medication and IVD resources for efficient patient management. Ultimately, this action has sparked a demand for various IVD tests and devices. Specific examples where IVD devices provide personalized medicine include pregnancy tests, blood glucose tests, in-home HIV tests, and screening of some types of cancer, including colon cancer.

The COVID-19 pandemic has led to a sharp rise in the demand for in-vitro diagnostic products. This trend can largely be attributed to an unprecedented surge in market demand for PCR, NGS, and serologybased rapid-test products. Notably, a very supportive regulatory environment for product development and commercialization and a substantial rise in the target patient population are other contributory factors. These factors have nudged the IVD diagnostics players to improve and strengthen their current manufacturing and distribution capabilities to meet the rising market demands. Let us know your thoughts.

    Top Emerging In Vitro Diagnostic Solutions Copmpanies

    Hopkins Medtech Compliance
    Hopkins MedTech Compliance is a CRO that assists drug developers and medical device manufacturers to navigate the regulatory approval process for their products. It guides them through each stage of the product lifecycle, from clinical development to commercialization, with a focus on robust clinical trial operations, quality assurance, and adherence to regulatory guidelines.
    Aldatu Biosciences
    Aldatu Biosciences advances the development of innovative diagnostic tools that drive our collective response to global health emergencies. Aldatu’s proprietary PANDAA qDx™ technology is a qPCR-enabling platform that overcomes long-standing diagnostic challenges to enhance the quality and affordability of high-throughput infectious disease diagnostics and improve patient access to diagnostics in resource-limited countries.
    Amplified Sciences
    Amplified Sciences is a life science diagnostics company focused on accurately detecting and pre-empting the risks of debilitating diseases with operations in Purdue Research Park and key alliances in San Francisco and Boston. The company’s lead assay is for the early detection of pancreatic cancer.
    CIGA Healthcare Ltd.
    Established in 2005, family owned CIGA Healthcare Ltd. has grown rapidly over the years. Based in Ballymena, Northern Ireland they supply a wide range of over-the-counter and professional tests to pharmacy outlets and health services under their Suresign brand which encompasses a broad range of medical devices and diagnostic tests.
    Devicia
    Devicia is a full-service partner offering regulatory and clinical expertise for medical devices and IVDs. The company offers consultancy services and expertise regarding strategy, quality assurance, regulatory affairs, clinical affairs and biocompatibility from a group of partner organizations, thereby providing an informed perspective along with support to clients throughout the life cycle of medical devices and IVD.
    Molzym
    Molzym is a developer and manufacturer of innovative products for molecular microbiology and microbial pathogen diagnostics. Products range from pre-analytical kits for the enrichment and extraction of microbial DNA to analytical PCR kits with ultra-clean DNA-free reagents and are distributed in more than 30 countries worldwide.
    Paratus Diagnostics
    Paratus Diagnostics is a biotech R&D company intended to advance the field of molecular testing and transform point-of-care diagnostics. The company specializes in creating point-of care diagnostic devices that can render lab quality results with convenience and precision, providing clients with accurate, efficient, and patient-friendly salivary tests.
    ResearchDx
    ResearchDx is a Contract Diagnostics Organization (CDO) for the biopharmaceutical and diagnostic industries. ResearchDx integrates and aligns IVD and biopharma development that simplifies, speeds, and ensures delivery of their clients’ FDA-approved companion diagnostics on time. They provide the solutions to meet complex diagnostics development needs.
    Scanogen
    Scanogen is a molecular diagnostic company developing a system to provide rapid and easy access to the biomolecular information of body fluids with the goal of improving health care. The company has developed Single MOLecule Tethering (SMOLT), a proprietary technology for rapid and ultra-sensitive detection of biomolecules.
    Zepto Life Technology
    Zepto Life Technology is on a mission to innovate and develop a highly-sensitive and multiplexed immunoassay and molecular diagnostics technology platform that can quickly diagnose diseases and determine medical interventions using a handheld device. Since 2014, Zepto Life Technology has been designing and developing its proprietary Gigantic Magneto-Resistance (GMR) biosensing chips, on-chip bio-surface technology, magnetic nanoparticle immunoassay, and microfluidic technology.

In Vitro Diagnostics Info

Q1
What Do Top In Vitro Diagnostics Solutions Do?
Top In Vitro Diagnostics Solutions support testing performed on samples such as blood, tissue, urine and swabs outside the body, usually in laboratories, hospitals or point-of-care settings. These solutions may involve instruments, reagents, assay platforms, sample preparation tools, workflow software or connected reporting systems. For healthcare organizations, the category sits close to clinical decision-making: test accuracy, turnaround time, sample integrity and result interpretation can affect diagnosis, treatment selection, infection control and patient follow-up.
Q2
Why Do Top In Vitro Diagnostics Solutions Matter Now?
It's critical for top In Vitro Diagnostics solutions because health teams must detect disease earlier, increase test volume and decrease turnaround time from collection to clinical decision, disease monitoring, molecular testing, distributed care, antimicrobial resistance, public health preparedness and other market dynamics will drive demand. Additionally, issues such as labor shortages, reimbursement challenges and quality expectations continue to stress labs and are factors in assessing in Vitro Diagnostics solutions based on ability to integrate into current capacity.
Q3
How Should Healthcare Decision-Makers Evaluate In Vitro Diagnostics Providers?
Decision-makers have to look at the width and breadth of the test menu, analytical capability, regulatory clearance status, throughput, maintenance requirements, reliability of reagents and interface with the LIMS. Also need to consider training, particularly if it's a platform that will be deployed across several sites or near the patient. Good vendors make validation, quality control, service response and documentation easier for laboratory directors, clinicians and those doing purchasing; a poor fit often shows up much later.
Q4
What Value Can In Vitro Diagnostics Solutions Create for Care Delivery?
Top in vitro diagnostics solutions create the most value when they help clinicians move faster from sample collection to clear clinical decisions. Rapid infectious disease testing can help care teams respond sooner and make timely isolation decisions. More accurate molecular assays can guide treatment selection with greater confidence. Improved sample tracking can reduce lost specimens, paperwork errors and delays caused by manual reconciliation. The impact goes beyond speed alone. Reliable diagnostics can help avoid unnecessary follow-up visits, support earlier treatment and give clinicians clearer direction when symptoms are difficult to interpret. For patients, that often means less waiting, less uncertainty and a clearer understanding of what comes next.
Q5
How Are Technology and Expertise Changing This Category?
Automation, digital connectivity and AI-assisted interpretation are reshaping diagnostics, but experienced laboratory teams still play a critical role. In real lab environments, platforms must consistently manage differences in specimen quality, calibration needs, error alerts and routine quality checks without disrupting workflow. Software can make routing, result review and disease surveillance more efficient, but clinicians and laboratory leaders still need systems they can understand, trust and confidently govern. The strongest in vitro diagnostics providers recognize that testing is not just about delivering an instrument or assay. They combine scientific expertise, reliable engineering, data management and responsive service support to help laboratories operate smoothly under everyday clinical pressures.
Q6
What Should Healthcare Organizations Prioritize When Comparing Options?
Healthcare organizations comparing Top In Vitro Diagnostics Solutions should prioritize clinical reliability, implementation fit, lifecycle cost, service coverage and reporting integration. A lower upfront price may be less attractive if reagent availability is uncertain or maintenance causes repeated downtime. Decision-makers should also look at scalability across departments, cybersecurity expectations for connected systems and the provider’s ability to support audits, staff training and software updates. The strongest choice is usually the one that protects result quality while reducing friction for the laboratory team.